|
|
成人EB病毒感染的临床特征、诊断及治疗进展
|
Abstract:
EB病毒(Epstein-Barr Virus, EBV)是人类疱疹病毒家族的一员，全世界90%以上的成人都感染过EBV。部分患者感染EBV后，可出现传染性单核细胞增多症、慢性活动性EB病毒感染(Chronic Active Epstein-Barr Virus Infection, CAEBV)以及与淋巴增生性疾病相关的癌症等。本文综述了成人EB病毒感染的临床特征、诊断方法及治疗进展，重点详细描述了治疗进展。
Epstein-Barr Virus (EBV), a member of the human herpesvirus family, infects over 90% of adults worldwide. Some individuals experience infectious mononucleosis, chronic active Epstein-Barr virus infection (CAEBV), or EBV-associated lymphoproliferative disorders and cancers following infection. This paper reviews the clinical characteristics, diagnostic methods, and recent advances in the treatment of EBV infection in adults, with a detailed focus on recent therapeutic advancements.
| [1] | Dunmire, S.K., Verghese, P.S. and Balfour, H.H. (2018) Primary Epstein-Barr Virus Infection. Journal of Clinical Virology, 102, 84-92. https://doi.org/10.1016/j.jcv.2018.03.001 |
| [2] | Lin, J., Su, M., Zheng, J., Gu, L., Wu, H., Wu, X., et al. (2022) Fas/FasL and Complement Activation Are Associated with Chronic Active Epstein-Barr Virus Hepatitis. Journal of Clinical and Translational Hepatology, 11, 540-549. https://doi.org/10.14218/jcth.2022.00227 |
| [3] | Shannon-Lowe, C., Rickinson, A.B. and Bell, A.I. (2017) Epstein-Barr Virus-Associated Lymphomas. Philosophical Transactions of the Royal Society B: Biological Sciences, 372, Article 20160271. https://doi.org/10.1098/rstb.2016.0271 |
| [4] | Xu, N., Fan, H.W., Huang, X.M., Wang, Y. and Sha, Y. (2018) Clinical Features of Adult Patients with Chronic Active Epstein-Barr Virus Infection. Chinese Journal of Internal Medicine, 57, 811-815. |
| [5] | Kawamoto, K., Miyoshi, H., Seto, M., Kimura, H. and Ohshima, K. (2017) Subtype of Epstein-Barr Virus-Positive T/NK-Cell Disorder among Adult Patients in Japan. Journal of Clinical Pathology, 70, 1010-1016. |
| [6] | Cohen, J.I. (2003) Benign and Malignant Epstein-Barr Virus-Associated B-Cell Lymphoproliferative Diseases. Seminars in Hematology, 40, 116-123. https://doi.org/10.1016/s0037-1963(03)70003-1 |
| [7] | 全国儿童EB病毒感染协作组, 中华实验和临床病毒学杂志编辑委员会. EB病毒感染实验室诊断及临床应用专家共识[J]. 中华实验和临床病毒学杂志, 2018, 32(1): 2-8. |
| [8] | Schwarze, V., Lindner, F., Marschner, C., Negrão de Figueiredo, G., Rübenthaler, J. and Clevert, D. (2019) Single-Center Study: The Diagnostic Performance of Contrast-Enhanced Ultrasound (CEUS) for Assessing Focal Splenic Lesions Compared to CT and MRI. Clinical Hemorheology and Microcirculation, 73, 65-71. https://doi.org/10.3233/ch-199204 |
| [9] | Tahara, M., Maekura, T., Kasai, T. and Akira, M. (2017) Primary Pulmonary MALT Lymphoma with Ground-Glass Nodule. Internal Medicine, 56, 3119-3120. https://doi.org/10.2169/internalmedicine.9000-17 |
| [10] | Xiang, Y., Liu, C., Xue, Y., Li, S., Sui, Y., Li, J., et al. (2020) Primary Central Nervous System Lymphomatoid Granulomatosis: Systemic Review. Frontiers in Neurology, 11, Article 901. https://doi.org/10.3389/fneur.2020.00901 |
| [11] | Lu, X., Wei, A., Yang, X., Liu, J., Li, S., Kan, Y., et al. (2022) The Role of Pre-Therapeutic 18F-FDG PET/CT in Pediatric Hemophagocytic Lymphohistiocytosis with Epstein-Barr Virus Infection. Frontiers in Medicine, 8, Article 836438. https://doi.org/10.3389/fmed.2021.836438 |
| [12] | Leung, A.K.C., Lam, J.M. and Barankin, B. (2024) Infectious Mononucleosis: An Updated Review. Current Pediatric Reviews, 20, 305-322. https://doi.org/10.2174/1573396320666230801091558 |
| [13] | Gomes, K. and Goldman, R.D. (2023) Corticosteroids for Infectious Mononucleosis. Canadian Family Physician, 69, 101-102. https://doi.org/10.46747/cfp.6902101 |
| [14] | Caillard, S. and Green, M. (2019) Prevention and Treatment of EBV-Related Complications. In: Infectious Diseases in Solid-Organ Transplant Recipients, Springer, 81-91. https://doi.org/10.1007/978-3-030-15394-6_7 |
| [15] | Haverkos, B.M., Alpdogan, O., Baiocchi, R., Brammer, J.E., Feldman, T.A., Capra, M., et al. (2021) Nanatinostat (Nstat) and Valganciclovir (VGCV) in Relapsed/refractory (R/R) Epstein-Barr Virus-Positive (EBV+) Lymphomas: Final Results from the Phase 1b/2VT3996-201 Study. Blood, 138, 623-623. https://doi.org/10.1182/blood-2021-152603 |
| [16] | Ebell, M.H. (2004) Epstein-Barr Virus Infectious Mononucleosis. American Family Physician, 70, 1279-1287. |
| [17] | Troger, A., Burrel, S., Pineton de Chambrun, M., Schmidt, M., Bréchot, N., Bomme, O., et al. (2022) Preemptive Acyclovir to Prevent Herpes Simplex Virus Bronchopneumonitis in Mechanically Ventilated Patients with Herpes Simplex Virus Oropharyngeal Reactivation: An Ancillary Study of the Preemptive Treatment for Herpesviridae Trial. Antiviral Therapy, 27, 1-8. |
| [18] | Abdulkarim, B., Sabri, S., Zelenika, D., Deutsch, E., Frascogna, V., Klijanienko, J., et al. (2003) Antiviral Agent Cidofovir Decreases Epstein-Barr Virus (EBV) Oncoproteins and Enhances the Radiosensitivity in EBV-Related Malignancies. Oncogene, 22, 2260-2271. https://doi.org/10.1038/sj.onc.1206402 |
| [19] | Liu, J., Zhang, J., Zhan, H., Sun, L. and Wei, L. (2021) EBV-Specific Cytotoxic T Lymphocytes for Refractory EBV-Associated Post-Transplant Lymphoproliferative Disorder in Solid Organ Transplant Recipients: A Systematic Review. Transplant International, 34, 2483-2493. https://doi.org/10.1111/tri.14107 |
| [20] | Alrashoudi, R. (2023) Unleashing the Power of Anti-Cd20 Immunotherapy: Mitigating Multiple Sclerosis Risk in Epstein-Barr Virus Latent Infections. Advances in Clinical and Experimental Medicine, 33, 869-880. https://doi.org/10.17219/acem/172240 |
| [21] | Jimenez, S. (2015) Epstein-Barr Virus-Associated Post-Transplantation Lymphoproliferative Disorder: Potential Treatments and Implications for Nursing Practice. Clinical Journal of Oncology Nursing, 19, 94-98. https://doi.org/10.1188/15.cjon.94-98 |
| [22] | Rao, M., Valentini, D., Dodoo, E., Zumla, A. and Maeurer, M. (2017) Anti-pd-1/pd-l1 Therapy for Infectious Diseases: Learning from the Cancer Paradigm. International Journal of Infectious Diseases, 56, 221-228. https://doi.org/10.1016/j.ijid.2017.01.028 |
| [23] | Bei, W., Dong, S., Liu, G., Lin, L., Jiang, Y., Lu, N., et al. (2024) Efficacy and Safety of Re-Challenging PD-1 Inhibitors in Second-Line Treatment in Metastatic Nasopharyngeal Carcinoma Previously Treated with Chemotherapy and PD-1 Inhibitors. Cancer Management and Research, 16, 771-780. https://doi.org/10.2147/cmar.s460716 |
| [24] | Prockop, S., Gamelin, L., Dinavahi, R., Sun, Y., Zhao, W., Galderisi, F., et al. (2021) Overall Survival by Best Overall Response with Tabelecleucel in Patients with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease Following Solid Organ or Allogeneic Hematopoietic Cell Transplant. Blood, 138, 887-887. https://doi.org/10.1182/blood-2021-147226 |
| [25] | Choquet, S., Clark, A., Renard, C., Uttenthal, B., Chaganti, S., Trappe, R.U., et al. (2023) Effectiveness and Safety Outcomes in Patients with Ebv+ PTLD Treated with Allogeneic EBV-Specific T-Cell Immunotherapy (Tabelecleucel) under an Expanded Access Program (EAP) in Europe. Journal of Clinical Oncology, 41, 7521-7521. https://doi.org/10.1200/jco.2023.41.16_suppl.7521 |
| [26] | Bollard, C.M. and Heslop, H.E. (2016) T Cells for Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant. Blood, 127, 3331-3340. https://doi.org/10.1182/blood-2016-01-628982 |
| [27] | Hanley, P.J., Shaffer, D.R., Cruz, C.R.Y., Ku, S., Tzou, B., Liu, H., et al. (2011) Expansion of T Cells Targeting Multiple Antigens of Cytomegalovirus, Epstein-Barr Virus and Adenovirus to Provide Broad Antiviral Specificity after Stem Cell Transplantation. Cytotherapy, 13, 976-986. https://doi.org/10.3109/14653249.2011.575356 |
| [28] | Zhang, Q., Zhang, B. and Chen, H. (2015) Cellular Immune Therapy for Epstein-Barr Virus Infection after Hematopoietic Stem Cell Transplantation. Chinese Association of Pathophysiology, 23, 1763-1768. |
| [29] | Sawada, A., Inoue, M. and Kawa, K. (2017) How We Treat Chronic Active Epstein-Barr Virus Infection. International Journal of Hematology, 105, 406-418. https://doi.org/10.1007/s12185-017-2192-6 |
| [30] | Kuriyama, T., Kawano, N., Yamashita, K. and Kikuchi, I. (2016) Cord Blood Transplantation Following Reduced-Intensity Conditioning for Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis during Systemic Lupus Erythematosus Treatment. Journal of Clinical and Experimental Hematopathology, 56, 126-129. https://doi.org/10.3960/jslrt.56.126 |
| [31] | Chen, X., Chen, Y., Lei, T., Yu, H., Li, C., Hong, Y., et al. (2023) PD-1 Blockade Combined with R-CHOP in Patients with Newly Diagnosed EBV-Positive Diffuse Large B-Cell Lymphoma: A Retrospective Analysis. Blood, 142, 4506-4506. https://doi.org/10.1182/blood-2023-182685 |
| [32] | Arai, A., Imadome, K., Watanabe, Y., Yoshimori, M., Koyama, T., Kawaguchi, T., et al. (2011) Clinical Features of Adult-Onset Chronic Active Epstein-Barr Virus Infection: A Retrospective Analysis. International Journal of Hematology, 93, 602-609. https://doi.org/10.1007/s12185-011-0831-x |
| [33] | Green, M. (2001) Management of Epstein-Barr Virus-Induced Post-Transplant Lymphoproliferative Disease in Recipients of Solid Organ Transplantation. American Journal of Transplantation, 1, 103-108. https://doi.org/10.1034/j.1600-6143.2001.10202.x |
| [34] | Dasari, V., Sinha, D., Neller, M.A., Smith, C. and Khanna, R. (2019) Prophylactic and Therapeutic Strategies for Epstein-Barr Virus-Associated Diseases: Emerging Strategies for Clinical Development. Expert Review of Vaccines, 18, 457-474. https://doi.org/10.1080/14760584.2019.1605906 |
